Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis

Wang, Hong; Cui, Manhua; Zhang, Shuangli; He, Jie; Song, Li; Chen, Ying

doi:10.1159/000484245

Cited by 4 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most of this data has been obtained from cellular models or includes a limited number of samples. In contrast, RASSF1A promoter hypermethylation has been reported as an early event in several types of cancers, such as breast [ 34 ], ovarian [ 35 ], endometrial [ 36 ], and cervical [ 37 ], and has been related with prognostic, surveillance, and treatment response. To our knowledge, this is the first report on REST protein level in SIL/CIN and SCC tissue samples and cervical cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

“…The presence of the RE1 sequence in RASSF1A suggested a transcription repression mediated by REST. Previously, loss of RASSF1A expression has been reported in several types of cancer [ [34] , [35] , [36] , [37] ]; particularly in cervical cancer, in which a significant difference between non-SIL, LSIL, HSIL and SCC has been reported [ 40 ]. This has also been linked to cancer development, progression, metastasis, and poor prognosis [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significant decrease of a master regulator of genes (REST/NRSF) in high-grade squamous intraepithelial lesion and cervical cancer

et al. 2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Significant decrease of a master regulator of genes (REST/NRSF) in high-grade squamous intraepithelial lesion and cervical cancer

et al. 2021

View full text Add to dashboard Cite

“…It plays an important role in the occurrence and development of esophageal cancer, which is consistent with the results of this group. It is suggested that RASSF1A is lowly expressed in esophageal squamous cell carcinoma tissues, which can accelerate the deterioration of cancer cells and promote the metastasis and invasion of cancer cells [29]. Kaplan–Meier single factor analysis showed that RASSF1A positive patients had higher survival time than negative patient.…”

Section: Discussionmentioning

confidence: 99%

RASSF-1A modulates proliferation-mediated oral squamous cell carcinoma progression

Sun

2019

Cancer Cell Int

View full text Add to dashboard Cite

Background To investigate the expression of RASSF-1A in oral squamous cell carcinoma (OSCC) and adjacent tissues, and to explore its mechanism of action in the development of OSCC. Methods RASSF-1A and proliferation-related protein expression in clinical and OSCC mouse models were detected by qPCR and western blot. In vitro experiments were used siRNA knockdown of RASSF-1A gene in SCC9 cells to detect cell proliferation, migration and apoptosis. In vivo experiments were performed using adenovirus overexpressing RASSF-1A gene in mice and observing tumor growth. Results The results of qPCR and western blot showed that the expression of RASSF-1A gene was decreased in OSCC, and the expression of CyclinD1 protein was increased. The results of co-immunoprecipitation showed that the two proteins were significantly combined in the oral cancer cell line. Knocking down the RASSF-1A gene in SCC9 cells promotes cell migration and proliferation, while reducing apoptosis and increasing CyclinD1 protein expression. Overexpression of RASSF-1A gene in mice reduces tumor volume and inhibits CyclinD1 protein expression. Conclusions Low expression of RASSF-1A gene in OSCC promotes the expression of CyclinD1 protein and tumor growth.

show abstract

“…RASSF1A promoter methylation has been reported to be markedly associated with EOC in a previous study on OC in Vietnamese women ( 64 ). However, a meta-analysis found that the levels of this modification were not substantially linked to the clinicopathological characteristics or the survival outcomes of patients with OC ( 65 ). This discrepancy may be due to differences in sample size or individual variations in experimental results.…”

Section: Tumor Suppressor Genesmentioning

confidence: 99%

Current data and future perspectives on DNA methylation in ovarian cancer (Review)

Fu,

Deng,

Chen

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

Ovarian cancer (OC) represents the most prevalent malignancy of the female reproductive system. Its distinguishing features include a high aggressiveness, substantial morbidity and mortality, and a lack of apparent symptoms, which collectively pose significant challenges for early detection. Given that aberrant DNA methylation events leading to altered gene expression are characteristic of numerous tumor types, there has been extensive research into epigenetic mechanisms, particularly DNA methylation, in human cancers. In the context of OC, DNA methylation is often associated with the regulation of critical genes, such as BRCA1/2 and Ras-association domain family 1A. Methylation modifications within the promoter regions of these genes not only contribute to the pathogenesis of OC, but also induce medication resistance and influence the prognosis of patients with OC. As such, a more in-depth understanding of DNA methylation underpinning carcinogenesis could potentially facilitate the development of more effective therapeutic approaches for this intricate disease. The present review focuses on classical tumor suppressor genes, oncogenes, signaling pathways and associated microRNAs in an aim to elucidate the influence of DNA methylation on the development and progression of OC. The advantages and limitations of employing DNA methylation in the diagnosis, treatment and prevention of OC are also discussed. On the whole, the present literature review indicates that the DNA methylation of specific genes could potentially serve as a prognostic biomarker for OC and a therapeutic target for personalized treatment strategies. Further investigations in this field may yield more efficacious diagnostic and therapeutic alternatives for patients with OC.

show abstract

Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis

Cited by 4 publications

References 50 publications

Significant decrease of a master regulator of genes (REST/NRSF) in high-grade squamous intraepithelial lesion and cervical cancer

Significant decrease of a master regulator of genes (REST/NRSF) in high-grade squamous intraepithelial lesion and cervical cancer

RASSF-1A modulates proliferation-mediated oral squamous cell carcinoma progression

Current data and future perspectives on DNA methylation in ovarian cancer (Review)

Contact Info

Product

Resources

About